BRAF and neoplasm: However, the data show a discrepancy between OS and PFS results, with a clear advantage in OS for patients with RAS/BRAF/EGFR mutant experiencing a high-grade ST that is not reflected in PFS, which remains poor and comparable to the subgroups of patients with G0–1 skin toxicity, independently from the RAS/BRAF/EGFR WT or mutant status.